Previous discussions have indicated that the small increases of risk of ven
ous thromboembolism (VTE) associated with newer combined oral contraceptive
s (third generation, containing desogestrel and gestodene) may be attribute
d to bias due to cohort effects. In a case-control analysis, this may produ
ce an overestimate of risk of newer preparations. In 10 centres in Germany
and the UK, the Transnational Study analysed data from 502 women aged 16-44
years with VTE, and from 1864 controls matched for 5-year age group and re
gion. Information on lifetime exposure history from all subjects was added
to the dataset used in previous analyses and entered into a Cox regression
model with time-dependent covariates. Based on 17 622 continuous exposure e
pisodes comprising 47 914 person-years of observation, the adjusted hazard
ratio (equivalent to odds ratio, OR) of VTE for the comparison of current u
sers of third-generation versus current users of second-generation (primari
ly levonorgestrel compounds) combined oral contraceptives was 0.8 (0.5 to 1
.3). The OR obtained in standard case-control analysis had been 1.5 (1.1 to
2.1). Adjustment for past exposures includes more information and appears
more valid than the standard cross-sectional analysis, Using this approach,
the Transnational Study data show no evidence for an increased risk of VTE
with third- compared with second-generation combined oral contraceptives.